Natco Pharma shifts focus from US, to spend 70% funds in emerging markets

60-70% of the R&D spend will be for developing portfolio in Brazil, Canada, China & India

Natco Pharma, which draws bulk of its revenues from the US market, thanks to successful products like generic Copaxone, is now turning its focus on Brazil, Canada, and China to fuel growth and also de-risk business model. The Hyderabad-based company is spending 60-70 per cent of its money on these emerging markets and India and only 30 per cent is being spent on the US market. 

In FY18, the US markets contributed $127 million or about 40 per cent of its FY18 turnover of $334 million. The contribution from the domestic market, rather, was lower at $112 million. 

Rajeev Nannapaneni, vice-chairman and